Fujifilm completes acquisition of Atara's cell therapy manufacturing site near Los Angeles
In January, Atara Biotherapeutics inked a deal with Fujifilm Diosynth to exchange its California manufacturing site for $100 million upfront, and a long-term licensing deal for its allogeneic T-cell therapy platform for patients with cancer and autoimmune disease. Monday, the biotech announced that the deal has now been completed, and the partnership has begun.
Fujifilm Diosynth will now give Atara access to the flex capacity to manufacture both clinical and commercial stage therapies for tab-cel, its off-the-shelf, allogeneic T-cell immunotherapy in development for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease, its candidate ATA188 for multiple sclerosis, and allogeneic CAR-T therapies ATA3271 and ATA3219.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.